TrialBlood advances2020

Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL.

Rakesh Awasthi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.